Targeting Factor XI for Safer Anticoagulation: Emerging Data and Future Directions.
用户d4Z4B36RBsr8
1个月前
88
10
已关闭
DOI:
文献链接:
其他信息:
F Campanella, F Barreca, S Giubilato…
American Journal of …, 2026
europepmc.org
Despite major advances with direct oral anticoagulants (DOACs), the clinical challenge of minimizing bleeding without losing efficacy remains unresolved. Factor XI (FXI) plays a pivotal role in thrombosis with limited contribution to hemostasis, making it an attractive target for novel anticoagulant therapy. Inhibition of FXI or its active form, FXIa, may therefore achieve effective antithrombotic protection while reducing the risk of bleeding. This review summarizes the biological rationale for targeting FXI, key pharmacological features of …
